Sinus Bradikardia

01Pathophysiology

The SA node is the dominant pacemaker of the heart. Under normal conditions, it fires at an intrinsic rate of 60 to 100 beats per minute. Sinus bradycardia occurs when the SA node discharge rate falls below 60 bpm while still maintaining its role as the primary pacemaker. This distinction is important: the rhythm is still originating from the SA node, and the conduction pathway through the atria, AV node, and ventricles remains intact. That is what separates sinus bradycardia from other causes of a slow heart rate like junctional escape rhythms or heart block.

Increased parasympathetic (vagal) tone is the most common mechanism. The vagus nerve releases acetylcholine at the SA node, which activates muscarinic M2 receptors. This increases potassium conductance through IKACh channels, hyperpolarizing the SA node cell membrane and slowing the rate of spontaneous depolarization during phase 4. The result is a longer interval between each heartbeat, and thus a slower rate. This is why athletes develop physiologic bradycardia: chronic aerobic training enhances resting vagal tone.

In pathologic states, the mechanism may be extrinsic or intrinsic. Extrinsic causes include medications that suppress SA node automaticity (beta-blockers antagonize sympathetic input, calcium channel blockers reduce calcium-dependent depolarization, digoxin enhances vagal tone). Hypothyroidism reduces basal metabolic rate and directly decreases SA node firing. Hypothermia slows all enzymatic and electrical activity in the heart. Raised intracranial pressure triggers the Cushing reflex, producing bradycardia through a vagal surge (this is a classic vignette setup: head trauma patient with hypertension, bradycardia, and irregular respirations).

Intrinsic causes involve structural damage to the SA node itself. Inferior myocardial infarction is the most tested ischemic cause, because the right coronary artery (RCA) supplies the SA node in approximately 60% of patients. Fibrosis and degeneration of the conduction system with aging leads to sick sinus syndrome, which may manifest as persistent inappropriate sinus bradycardia, sinus pauses, or tachy-brady syndrome.

The symptoms of sinus bradycardia are explained directly by the drop in cardiac output. According to the equation $CO=HR\times SVCO\; =\; HR\; \backslash times\; SV$, a sufficient drop in heart rate reduces cardiac output even if stroke volume is preserved. This leads to decreased cerebral perfusion (causing lightheadedness, syncope) and decreased systemic perfusion (causing fatigue, exercise intolerance, and in severe cases, hypotension or shock).

02Classification and Clinical Manifestation

03Diagnostic Workup

The best initial test is always a 12-lead ECG. This is what confirms you are dealing with sinus bradycardia rather than another cause of a slow heart rate. You are looking for a regular rhythm, a rate below 60 bpm, and the hallmark feature: a normal, upright P wave preceding every QRS complex in leads I and II with a constant PR interval. If P waves are absent, inverted in lead II, or dissociated from QRS complexes, you are not dealing with sinus bradycardia, and you need to consider junctional rhythm or AV block.

Once the rhythm is confirmed, the next question is: why does this patient have bradycardia? This is where the labs come in. Order a TSH to screen for hypothyroidism, a basic metabolic panel to check potassium (hyperkalemia) and renal function (affects drug clearance), and drug levels if the patient is on digoxin or lithium. If the clinical picture suggests acute coronary syndrome (chest pain, diaphoresis, ST changes), troponin is essential.

For patients with intermittent symptoms (e.g., episodic near-syncope with a normal resting ECG), a Holter monitor (24 to 48 hours) or an event monitor (worn for weeks) is ordered to catch the arrhythmia in action and correlate rhythm disturbances with symptoms.

If intrinsic SA node disease (sick sinus syndrome) is strongly suspected but noninvasive testing is inconclusive, an electrophysiology study is the most accurate test. The corrected sinus node recovery time (cSNRT) is measured by pacing the atrium at progressively faster rates, then stopping to see how long the SA node takes to resume firing. A cSNRT greater than 550 milliseconds indicates SA node dysfunction.

04Management and Treatment

Step 1: Assess hemodynamic stability. This is the fork in every bradycardia question. Ask: Is the patient symptomatic? Are there signs of poor perfusion (hypotension, altered mental status, chest pain, acute heart failure)? If the patient is asymptomatic and hemodynamically stable, the answer is observation and monitoring. Do not treat asymptomatic sinus bradycardia. A well-trained athlete with a resting heart rate of 45 bpm and no symptoms requires zero intervention.

Step 2: If symptomatic and unstable, give atropine. Atropine is an antimuscarinic agent that blocks vagal input to the SA node, allowing the intrinsic sympathetic tone to increase the heart rate. The dose is 0.5 mg IV push, repeated every 3 to 5 minutes up to a maximum total of 3 mg. A critical testing point: doses below 0.5 mg can paradoxically worsen bradycardia through a central vagotonic effect. Never give mini-doses.

Step 3: If atropine fails, initiate transcutaneous pacing. This is a temporizing measure. Place pads anteriorly and posteriorly, set the rate to 60 to 80 bpm, and increase the milliamp output until you see electrical capture (a pacing spike followed by a wide QRS). Confirm mechanical capture by checking for a pulse with each complex. This bridges the patient to transvenous pacing if needed.

Step 4: Pharmacologic alternatives while awaiting pacing. A dopamine drip (5 to 20 mcg/kg/min) or an epinephrine drip (2 to 10 mcg/min) can be used as chronotropic support if pacing is not immediately available.

Step 5: Identify and treat reversible causes. This is the highest-yield management principle. If the bradycardia is from beta-blocker overdose, the antidote is glucagon (3 to 10 mg IV bolus, followed by infusion). For digoxin toxicity, give digoxin-specific antibody fragments (Digibind/DigiFab). For hypothyroidism, start levothyroxine. For hyperkalemia, treat the potassium. If raised intracranial pressure is the cause, address the intracranial pathology. Bradycardia from inferior MI is often transient and resolves with reperfusion; temporary pacing may be needed as a bridge.

Step 6: Long-term management. For patients with irreversible symptomatic bradycardia (sick sinus syndrome, chronotropic incompetence, tachy-brady syndrome requiring rate-controlling drugs), the definitive treatment is a permanent pacemaker. The most common indication tested is symptomatic bradycardia that cannot be attributed to a reversible or correctable cause.

Contraindications and cautions:

• Atropine is ineffective in heart transplant patients because the transplanted heart is denervated and does not respond to vagolytic agents. Go directly to pacing or chronotropic infusions.

• Atropine should be used with caution in acute MI because increasing the heart rate can worsen ischemia by raising myocardial oxygen demand.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common mistake students make with sinus bradycardia questions is treating a stable, asymptomatic patient. The test-writer will present a young, athletic patient with a heart rate of 48 bpm found incidentally on a pre-operative ECG, with a completely normal physical exam and no symptoms. Every answer choice will tempt you to intervene: atropine, pacemaker referral, further workup. The correct answer is reassurance and no treatment. The core competency here is recognizing that physiologic sinus bradycardia in a conditioned individual is normal and benign.

The second major trap is the atropine dosing pitfall. If the vignette describes a patient who received atropine and the bradycardia worsened, the stem is testing whether you know that sub-therapeutic doses (below 0.5 mg) can cause paradoxical bradycardia. The correct next step is to give a full 0.5 mg dose, not to abandon atropine entirely.

Third, watch for the inferior MI bradycardia vignette. When a patient presents with chest pain, ST elevation in leads II, III, and aVF, and sinus bradycardia, the question is testing your understanding that the RCA supplies both the inferior myocardium and the SA node. The bradycardia is a consequence of the infarction. Manage the MI (reperfusion is the priority), and the bradycardia typically resolves. Do not jump to permanent pacemaker.

Finally, be alert for the denervated heart question. If the patient is a heart transplant recipient with symptomatic bradycardia, atropine will not work. The answer is transcutaneous pacing or a chronotropic agent (isoproterenol, epinephrine), not atropine. This tests your understanding of the mechanism of atropine (parasympathetic blockade), which is useless when the nerve supply to the heart has been surgically severed.